Skip to main content
. Author manuscript; available in PMC: 2017 Aug 14.
Published in final edited form as: Cell. 2016 Dec 1;167(6):1481–1494.e18. doi: 10.1016/j.cell.2016.11.013

Figure 7. Normalization of Tie2Cre;Slc7a5fl/fl mouse behavior after leucine and isoleucine i.c.v. administration.

Figure 7

(A) Timeline of treatment and HPLC and behavioral tests.

(B) Brain levels of leucine (left) and isoleucine (right) in age-matched animals receiving (+) or not receiving (−) the i.c.v. treatment. Amino acid levels were normalized to protein concentration and to wild-type levels. **P<0.01, ***P<0.001 (means ± SEM; n=8 mice/genotype).

(C) Quantification of the total distance moved (left), velocity (middle) and number of rearings (right) in the open field revealing similar behavior in treated (+) Tie2Cre;Slc7a5fl/fl mice and non-treated (−) or treated (+) controls (Tie2Cre;Slc7a5fl/+) but significant differences with non-treated (−) Tie2Cre;Slc7a5fl/fl mice; *P<0.05, **P<0.01 (means ± SEM; n=10 (−) control, n=4 (+) control, n=11 (−) mutant and n=8 (+) mutant).

(D) Similar sway length in treated (+) mutant mice and non-treated (−) or treated (+) control (Tie2Cre;Slc7a5fl/+) animals but significant difference with non-treated (−) Tie2Cre;Slc7a5fl/fl mice; **P<0.01 (means ± SEM; n=10 (−) control, n=4 (+) control, n=11 (−) mutant and n=8 (+) mutant).

See also Table S3.